Nathaniel Katz, MD, MS Analgesic Solutions, Natick, MA Tufts University School of Medicine, Boston, MA IMMPACT-XVIIIW ASHINGTON, DC J UNE 4-5, 2015.

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Informed Consent.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:
Essential Documentation GCP Training Seminar 12th October 2011
Tips to a Successful Monitoring Visit
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Evaluation of Pain Drugs: Role of Undetected Underlying Sleep Pathologies Barry T. Peterson, PhD*, Jeremiah Trudeau, PhD**, Nathaniel Katz, MD** *Philips.
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
Standard operating procedures the blueprint of research Cluj-Napoca, Romania 2014 June 17th Oana M. Pop MA Cluj School of Public Health College of Political,
Practical Effective Steps to Improve Trial QUALITY from Audit/Inspections findings Cancer Clinical Trials Unit Scotland A NCRI Accredited Cancer Trials.
Managing Sponsorship Research Services University of Oxford.
Chapter 2 Health Care Information Systems: A Practical Approach for Health Care Management 2nd Edition Wager ~ Lee ~ Glaser.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Biostatistics. But why? Why do we read scientific litterature? How do we read scientific litterature?
ABS Health, LLC 12466, E Washington Blvd, Whittier, CA – Phone
How Science Works Glossary AS Level. Accuracy An accurate measurement is one which is close to the true value.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Scott D. Duncan, MD, MHA, FAAP. Science of Safety We cannot improve quality and safety of healthcare until we view the everyday delivery of healthcare.
Overview of Good Clinical Practices (GCPs)
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Introduction to Clinical Protocol
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases Division, University of Louisville Chief, Infectious Diseases Section, Veterans.
A Regulatory Perspective on Threats to the Integrity of Analgesic Clinical Trial Efficacy Data Sharon Hertz, MD Division Director Division of Anesthesia,
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Minimum Standards and Exemplary Attributes of Clinical Trial Sites S. Gail Eckhardt, MD (Slides prepared by Robin Zon, MD)
Seminar THREE The Patient Record:
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Simple Comparative Experiments Section 2.3. More on Experiments An experiment is a planned intervention undertaken to observe the effects of one or more.
24 Nov 2007Data Management and Exploratory Data Analysis 1 Yongyuth Chaiyapong Ph.D. (Mathematical Statistics) Department of Statistics Faculty of Science.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
New from 2013… to 2017 Declaration of Helsinki 2013 Updated definition of Critical Audit Finding from HRA April 2014 European Regulation 2014 Care Act.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
The Trial Master File What is it? What’s in it? Lisa Mulcahy.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Data Management in Clinical Research
The Role and Responsibilities of the Clinical Research Coordinator
Data Integrity – The Basis for “Generalizability” to Substantiate Change Balancing Efficacy with Clinical Power Frederick A. Curro, DMD, PhD PEARL Network.
Stephanie Oppenheimer, MS SUCCESS Center Erica Ellington, CRA, CHRC
Responsibilities of Sponsor, Investigator and Monitor
OUS Data: What does the CE Mark Really Mean?
FDA Division of Cardiovascular Devices
MAINTAINING THE INVESTIGATOR’S SITE FILE
NIH Clinical Trial Requirements
Leigh E. Tenkku, PhD, MPH Department of Family and Community Medicine
The Role of Statistics in Clinical Trials
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Monitoring Reports that Assist with Remote Monitoring
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Good afternoon everyone
Code of Ethics for CDM Professionals
Code of Ethics for CDM Professionals
Good clinical practice
Psychological Experimentation
Presentation transcript:

Nathaniel Katz, MD, MS Analgesic Solutions, Natick, MA Tufts University School of Medicine, Boston, MA IMMPACT-XVIIIW ASHINGTON, DC J UNE 4-5, 2015

2 Quality Regulatory Quality Scientific Quality Principles of experimentation Definitions Science of clinical study conduct Manufacturing quality

RatingFinding CriticalInadequate security system in facility CriticalSOPs 2 days out of date Handwritten notes found on some SOPs CriticalNo independent Quality Assurance department Missing independent vendor audits CriticalCertain protocol versions in TMF lacking signatures One version of the ICF missing from TMF CRF approval form missing a signature CriticalSection 10.4 of TMF referred to section 10.4 instead of 10.3 A CV was 2 weeks beyond update window CriticalInconsistency between Site Submission Form and Delegation of Authority Log 3

4 Bud Fisher, Mutt and Jeff comic strip, June 3, 1942

6

Ball LK, CTTI Meeting, October

8 What is the magnitude of effect of treatment compared to placebo. Quality means minimizing sources of error that compromise the accuracy of measurement of treatment effect. This is a measurement task. A clinical trial can be considered a measurement system, designed to measure the magnitude of efficacy of a treatment.

9 Perspective courtesy of Paul Desjardins Sources of experimental error: Type of surgery Timing of assessments Training of coordinator Dressings Timing of PT Rescue medication

10 InputOutput Hold everything else constant!

 Fraud & data fabrication  Study design errors  Errors in pain measurement  Unreliable/invalid pain endpoint  Poor pain reporting  Study conduct errors  Protocol violations  Compromised randomization or blinding  Poor medication compliance  Variable patient expectation  Non-study treatments  Covariates  Activity  Sleep  Assistive devices  Additional treatments  Data storage and management  Data entry or transformation errors  Data analysis  Faulty statistical analysis plan or execution 11

13 Variables that reflect study quality Baseline pain variability 1 Subject enrollment rate 2 Placebo response rate 3 E-diary compliance 4 Medication adherence 4 Correlation between two different pain measures 4 Subject ability to report pain accurately 5 1. Farrar J, Pain, 2014; 2. Singla N, J Pain Res, 2014; 3. Katz J, Neurology, 2008; 4. Katz N, American Pain Society, May 2015; 5. Trudeau J, IASP, 2012

14 Walter A. Shewhart W. Edwards Deming

 Process: a unique combination of tools, materials, methods, and people engaged in producing a measurable output; for example a manufacturing line for machine parts  Control chart (or process behavior chart): a graphical display illustrating variation over time in the output of a process, usually showing boundaries of statistical control limits 15

Study View Site View Metric View Subject View

 Quality in clinical trials is the identification and minimization of sources of error that compromise accuracy of measurement of treatment effect  Quality control rests on evidence that specific variables, amenable to surveillance, are relevant to study output  Variables that appear to influence study output include pain variability, accuracy of pain reporting, medication compliance, and diary compliance  From a statistical quality control perspective, a clinical trial can be conceived as a process (with many components), yielding a measurable output (a measurement of magnitude of treatment effect)  Further research is needed to further define relevant quality variables and the best method for surveillance and correction 17